Raymond James initiates Nektar stock coverage with Market Perform
Raymond James initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating, citing its focus on autoimmune therapies and cash burn. The stock is down 46% over six months, with a market cap of $1.39 billion. Nektar reported a smaller-than-expected Q2 2026 loss but missed revenue forecasts. The company won a $90 million verdict against Eli Lilly and received a Buy rating with a $185 price target from H.C. Wainwright.
How this was made
The 30-second read
Why it matters
The fresh legal win and coverage are likely to generate short‑term buying interest, though cash‑flow constraints remain a risk.
Market read
New legal award and analyst coverage provide a fresh catalyst for NKTR, offering a modest trading opportunity.
What to watch
Potential appeal by Eli Lilly could delay cash receipt; the Market Perform rating is neutral, not a buy.
Background
The article combines an analyst initiation note with a newly disclosed $90 M legal award and a recap of Q2 earnings that had been released weeks earlier.
Ticker impact
Raymond James initiated coverage with a Market Perform rating and Nektar was awarded a $90 million jury verdict against Eli Lilly, both new events disclosed in this article.
likely upward pressure as the market prices in the verdict and new buy‑side rating.
The $90 M award removes a legal risk and the initiation report adds analyst visibility, which typically lifts the stock.
Market effects
May boost sentiment toward biotech firms with pending litigation or partnership disputes.
Limited to U.S. biotech sector; no broader regional effect.
Minor; primarily affects NKTR and peers monitoring litigation outcomes.
Counterpoint
The verdict may be offset by ongoing cash‑burn concerns and a recent revenue miss.
Key entities
- companyNektar Therapeutics
Biotech developing T‑reg therapies, ticker NKTR.
- analyst_firmRaymond James
Initiated coverage with Market Perform rating.
- companyEli Lilly
Defendant in the $90 M breach‑of‑contract lawsuit.
